A Phase 1 interventional study of IV Acetaminophen and IV Acetaminophen in Pain and Fever, sponsored by Mallinckrodt. Completed at 5 sites in United States. Open to participants aged 29 Days to 16 Years. Per ClinicalTrials.gov, last updated 2016-10-21.
Sponsored by Mallinckrodt · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.
Among the 137 studies testing acetaminophen in Pain, this one is the 83rd largest by enrollment, is one of 8 that started in 2007, is one of 11 in phase 1, and was the 17th registered.
10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.
Browse Pain studies →5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
Horizon Health Network · Sites in Canada
Ages 19+
University of Gaziantep · Sites in Turkey
Ages 18–75
Western Galilee Hospital-Nahariya · Sites in Israel
Ages 18–45 · Women only · Healthy volunteers
Baskent University · Sites in Turkey
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.
This study: 29 Days to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
137 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 25 · Phase 4 67
First in 2003; this study’s year is marked. 8 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is above the median of 66 across 8,511 interventional studies indexed under Pain.
Median enrollment 95 across the 137 interventional studies. Of the 115 that completed or were terminated, 53 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 137 have an industry lead sponsor. The 10 most frequent:
This study is registered under Mallinckrodt, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Mallinckrodt is the lead sponsor of 87 studies on the registry; none are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 15 (100%) have results posted.
16 studies in Pain by Keenova Therapeutics plc: none open now, none under way, none of them phase 3. Of 16 finished, 10 (63%) have results posted.
Among the 16 studies in Pain by Keenova Therapeutics plc, this one is the 10th largest by enrollment, is one of 3 that started in 2007, is one of 3 in phase 1, and was the 3rd registered.
Keenova Therapeutics plc’s Pain studies by the year they started, since 2001.
4 of the studies testing acetaminophen in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07512297University of GaziantepPain Control During ESWL Using Non-Opioid Analgesics | 2027-01-01 |
| NCT07368738Horizon Health NetworkIntravenous Acetaminophen and Ketorolac for Pain Management During Extracorporeal Shockwave Lithotripsy | 2027-04 |
| NCT06613178McGill University Health Centre/Research Institute of the McGill University Health CentreIntravenous Acetaminophen After Cardiac Surgery - Definitive Study | 2027-07-01 |
| NCT07536425Western Galilee Hospital-NahariyaPreoperative Indomethacin and Paracetamol for Pain Management During Oocyte Retrieval in IVF Patients | 2027-10-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 137 studies testing acetaminophen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Keenova Therapeutics plc’s 16 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
We are doing this study to find out what happens to acetaminophen in the body after it is given to children through the vein. Children's bodies may handle drugs differently than adults. Understanding how long the drug stays in the body and how the drug is changed or metabolized by the body (called pharmacokinetics) is an important step in learning what the best dose of acetaminophen for children should be. We are also interested in learning about the safety of this medication when given to children.
A Prospective, Multi-Center, Randomized, Open-Label, Single and Repeated Dose, 48 Hour Study, of Intravenous Acetaminophen in Pediatric Inpatients to Determine Pharmacokinetics (PK) and Safety in Acute Pain and Fever
To be eligible for entry into the Study, Subjects must meet or Subjects' Parent or Guardian must meet, agree with or confirm all of the following criteria:
Age strata:
Infants [29 days to \<2 years (yrs) old]
Exclusion Criteria (Screening)
A Subject is NOT eligible for entry if ANY of the following criteria are met:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous Acetaminophen administered 15 milligrams/kilogram (mg/kg) every 8 hours (q8h) or every 6 hours (q6h) based age of subject
Drug: IV Acetaminophen
Intravenous Acetaminophen administered 12.5 milligrams/kilogram (mg/kg) every 6 hours (q6h) or every 4 hours (q4h)
Drug: IV Acetaminophen
This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age) Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen
Also known as: APAP, IV APAP
This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age) Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen
Also known as: APAP, IV APAP
Single-dose Maximum Plasma Concentration (Cmax) , Micrograms Per Milliliter (µg/mL) Pharmacokinetics of IV Acetaminophen
Cmax: Maximum Plasma Concentration
Time frame: Time Zero (just prior to first dose) to 24 hours post first dose
Single-dose Time to Reach Maximum Plasma Concentration [Tmax(h)] Pharmacokinetics of IV Acetaminophen
Tmax: Time to reach maximum plasma concentration (Cmax)
Time frame: Time Zero (just prior to first dose) to 24 hours post first dose
Multiple-dose Area Und the Curve (AUC) From Time 0 (Predose) to the Time of the Dosing Interval at Steady-state (0-t (µg*h/ml) Pharmacokinetics of IV Acetaminophen
AUC 0-t (µg\*h/ml): Area under the plasma concentration versus time curve from time 0 (predose) to the time of the dosing interval at steady-state.
Time frame: Time Zero (just prior to first dose) to 48 hours post first dose
Multiple-dose Terminal Elimination Half-life [t1/2(h)] Pharmacokinetics of IV Acetaminophen
t1/2: Terminal elimination half-life
Time frame: 48hrs
Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE)
A TEAE is defined as an adverse event that starts on or after the start of study medication
Time frame: First dose of study medication to 30 days after the last dose of study medication
Subjects Who Experience at Least One Serious Treatment-Emergent Adverse Event (TEAE)
A Serious Treatment Emergent Adverse Event is defined as any untoward medical occurrence at any dose of IV acetaminophen that; Results in Death, Is life-threatening, Requires inpatient hospitalization or causes prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is an important medical event
Time frame: First dose to 30 days following last dose of study medication
The study was conducted at 5 sites in the US from 27 June 2007 to 01Sep 2008.
| Milestone | Neonates:12.5 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Neonates: 15 mg/kg Every 8 Hours (q8h) IV Acetaminophen | Infants: 12.5 mg/kg q4h IV Acetaminophen | Infants:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Children: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Children: 15 mg/kg Every 6 Hours(q6h) IV Acetaminophen | Adolescents: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Adolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen |
|---|---|---|---|---|---|---|---|---|
| Started | 2 | 1 | 12 | 13 | 9 | 16 | 12 | 10 |
| Completed | 2 | 1 | 12 | 13 | 8 | 15 | 11 | 10 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: No access to draw blood | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Cmax: Maximum Plasma Concentration
| micrograms per milliliter (µg/mL) | Neonates:12.5 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Neonates: 15 mg/kg Every 8 Hours (q8h) IV Acetaminophen | Infants: 12.5 mg/kg q4h IV Acetaminophen | Infants:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Children: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Children: 15 mg/kg Every 6 Hours(q6h) IV Acetaminophen | Adolescents: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Adolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen |
|---|---|---|---|---|---|---|---|---|
| Single-dose Maximum Plasma Concentration (Cmax) , Micrograms Per Milliliter (µg/mL) Pharmacokinetics of IV Acetaminophen | 40.1 (15.9 to 64.4) | 20.1 (20.1 to 20.1) | 16.7 (12.1 to 23.0) | 19.3 (16.2 to 25.4) | 18.2 (13.5 to 27.1) | 21.6 (14.4 to 60.8) | 15.9 (10.6 to 28.8) | 25.5 (9.91 to 49.8) |
Tmax: Time to reach maximum plasma concentration (Cmax)
| Hour | Neonates:12.5 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Neonates: 15 mg/kg Every 8 Hours (q8h) IV Acetaminophen | Infants: 12.5 mg/kg q4h IV Acetaminophen | Infants:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Children: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Children: 15 mg/kg Every 6 Hours(q6h) IV Acetaminophen | Adolescents: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Adolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen |
|---|---|---|---|---|---|---|---|---|
| Single-dose Time to Reach Maximum Plasma Concentration [Tmax(h)] Pharmacokinetics of IV Acetaminophen | 0.450 (0.400 to 0.500) | 0.333 (0.333 to 0.333) | 0.267 (0.000 to 0.383) | 0.267 (0.250 to 0.933) | 0.250 (0.0833 to 0.300) | 0.250 (0.0833 to 0.417) | 0.250 (0.0833 to 0.283) | 0.267 (0.00 to 0.333) |
AUC 0-t (µg\*h/ml): Area under the plasma concentration versus time curve from time 0 (predose) to the time of the dosing interval at steady-state.
| µg*h/ml | Neonates:12.5 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Neonates: 15 mg/kg Every 8 Hours (q8h) IV Acetaminophen | Infants: 12.5 mg/kg q4h IV Acetaminophen | Infants:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Children: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Children: 15 mg/kg Every 6 Hours(q6h) IV Acetaminophen | Adolescents: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Adolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen |
|---|---|---|---|---|---|---|---|---|
| Multiple-dose Area Und the Curve (AUC) From Time 0 (Predose) to the Time of the Dosing Interval at Steady-state (0-t (µg*h/ml) Pharmacokinetics of IV Acetaminophen | 65.6 (55.8 to 75.4) | 105 (105 to 105) | 43.3 (9.15 to 79.2) | 51.9 (36.0 to 200) | 37.8 (11.3 to 52.3) | 48.0 (32.2 to 131) | 47.7 (22.4 to 132) | 64.0 (33.2 to 84.1) |
t1/2: Terminal elimination half-life
| Hours | Neonates:12.5 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Neonates: 15 mg/kg Every 8 Hours (q8h) IV Acetaminophen | Infants: 12.5 mg/kg q4h IV Acetaminophen | Infants:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Children: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Children: 15 mg/kg Every 6 Hours(q6h) IV Acetaminophen | Adolescents: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Adolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen |
|---|---|---|---|---|---|---|---|---|
| Multiple-dose Terminal Elimination Half-life [t1/2(h)] Pharmacokinetics of IV Acetaminophen | 3.88 (3.88 to 3.88) | — | 2.37 (1.15 to 2.81) | 2.79 (2.10 to 5.43) | 2.64 (2.24 to 4.46) | 2.77 (2.15 to 4.85) | 3.37 (2.69 to 4.16) | 4.10 (2.48 to 4.36) |
A TEAE is defined as an adverse event that starts on or after the start of study medication
| Participants | Neonates:12.5 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Neonates: 15 mg/kg Every 8 Hours (q8h) IV Acetaminophen | Infants: 12.5 mg/kg q4h IV Acetaminophen | Infants:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Children: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Children: 15 mg/kg Every 6 Hours(q6h) IV Acetaminophen | Adolescents: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Adolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen |
|---|---|---|---|---|---|---|---|---|
| Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE) | 2 | 1 | 10 | 9 | 2 | 11 | 10 | 6 |
A Serious Treatment Emergent Adverse Event is defined as any untoward medical occurrence at any dose of IV acetaminophen that; Results in Death, Is life-threatening, Requires inpatient hospitalization or causes prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is an important medical event
| Participants | Neonates:12.5 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Neonates: 15 mg/kg Every 8 Hours (q8h) IV Acetaminophen | Infants: 12.5 mg/kg q4h IV Acetaminophen | Infants:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Children: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Children: 15 mg/kg Every 6 Hours(q6h) IV Acetaminophen | Adolescents: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Adolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen |
|---|---|---|---|---|---|---|---|---|
| Subjects Who Experience at Least One Serious Treatment-Emergent Adverse Event (TEAE) | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 1 |
Collected over Adverse Events and Serious Adverse Events were reported from the start of study medication to 30 days following the last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Neonates:12.5 mg/kg Every 6 Hours (q6h) IV Acetaminophen | — | 0/2 (0%) | 2/2 (100%) |
| Neonates: 15 mg/kg Every 8 Hours (q8h) IV Acetaminophen | — | 0/1 (0%) | 1/1 (100%) |
| Infants: 12.5 mg/kg q4h IV Acetaminophen | — | 0/12 (0%) | 10/12 (83.3%) |
| Infants:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen | — | 1/13 (7.7%) | 7/13 (53.8%) |
| Children: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | — | 1/9 (11.1%) | 1/9 (11.1%) |
| Children: 15 mg/kg Every 6 Hours(q6h) IV Acetaminophen | — | 2/16 (12.5%) | 10/16 (62.5%) |
| Adolescents: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | — | 1/12 (8.3%) | 10/12 (83.3%) |
| Adolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen | — | 1/10 (10%) | 5/10 (50%) |
| Event | Neonates:12.5 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Neonates: 15 mg/kg Every 8 Hours (q8h) IV Acetaminophen | Infants: 12.5 mg/kg q4h IV Acetaminophen | Infants:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Children: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Children: 15 mg/kg Every 6 Hours(q6h) IV Acetaminophen | Adolescents: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Adolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen |
|---|---|---|---|---|---|---|---|---|
| Thoracic cavity drainage test abnormalInvestigations | 0/2 | 0/1 | 0/12 | 0/13 | 1/9 | 0/16 | 0/12 | 0/10 |
| Abdominal PainGastrointestinal disorders | 0/2 | 0/1 | 0/12 | 0/13 | 0/9 | 0/16 | 0/12 | 1/10 |
| Post procedural drainageSurgical and medical procedures | 0/2 | 0/1 | 0/12 | 0/13 | 0/9 | 0/16 | 1/12 | 0/10 |
| ConvulsionNervous system disorders | 0/2 | 0/1 | 0/12 | 1/13 | 0/9 | 0/16 | 0/12 | 0/10 |
| Mediastinal disorders chylothoraxRespiratory, thoracic and mediastinal disorders | 0/2 | 0/1 | 0/12 | 0/13 | 0/9 | 1/16 | 0/12 | 0/10 |
| Wound infectionInfections and infestations | 0/2 | 0/1 | 0/12 | 0/13 | 0/9 | 1/16 | 0/12 | 0/10 |
| Event | Neonates:12.5 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Neonates: 15 mg/kg Every 8 Hours (q8h) IV Acetaminophen | Infants: 12.5 mg/kg q4h IV Acetaminophen | Infants:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Children: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Children: 15 mg/kg Every 6 Hours(q6h) IV Acetaminophen | Adolescents: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Adolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen |
|---|---|---|---|---|---|---|---|---|
| AtelectasisRespiratory, thoracic and mediastinal disorders | 1/2 | 1/1 | 1/12 | 2/13 | 0/9 | 3/16 | 1/12 | 0/10 |
| Pulmonary EdemaRespiratory, thoracic and mediastinal disorders | 0/2 | 1/1 | 2/12 | 1/13 | 1/9 | 0/16 | 0/12 | 0/10 |
| HypomagnesaemiaMetabolism and nutrition disorders | 1/2 | 0/1 | 3/12 | 1/13 | 0/9 | 1/16 | 1/12 | 1/10 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 1/2 | 0/1 | 4/12 | 0/13 | 0/9 | 3/16 | 1/12 | 1/10 |
| NauseaGastrointestinal disorders | 0/2 | 0/1 | 0/12 | 1/13 | 0/9 | 4/16 | 5/12 | 2/10 |
| PruritisSkin and subcutaneous tissue disorders | 0/2 | 0/1 | 1/12 | 1/13 | 0/9 | 5/16 | 1/12 | 2/10 |
| ConstipationGastrointestinal disorders | 0/2 | 0/1 | 0/12 | 2/13 | 0/9 | 1/16 | 2/12 | 0/10 |
| HypokalemiaMetabolism and nutrition disorders | 0/2 | 0/1 | 2/12 | 1/13 | 1/9 | 2/16 | 0/12 | 1/10 |
| StridorRespiratory, thoracic and mediastinal disorders | 0/2 | 0/1 | 2/12 | 1/13 | 0/9 | 0/16 | 0/12 | 0/10 |
| WheezingRespiratory, thoracic and mediastinal disorders | 0/2 | 0/1 | 2/12 | 2/13 | 0/9 | 0/16 | 0/12 | 0/10 |
| Age, Categorical(Participants) | Neonates:12.5 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Neonates: 15 mg/kg Every 8 Hours (q8h) IV Acetaminophen | Infants: 12.5 mg/kg q4h IV Acetaminophen | Infants:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Children: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Children: 15 mg/kg Every 6 Hours(q6h) IV Acetaminophen | Adolescents: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Adolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 2 | 1 | 12 | 13 | 9 | 16 | 12 | 10 | 75 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Neonates:12.5 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Neonates: 15 mg/kg Every 8 Hours (q8h) IV Acetaminophen | Infants: 12.5 mg/kg q4h IV Acetaminophen | Infants:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Children: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Children: 15 mg/kg Every 6 Hours(q6h) IV Acetaminophen | Adolescents: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen | Adolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 1 | 4 | 7 | 4 | 6 | 2 | 6 | 31 |
| Male | 1 | 0 | 8 | 6 | 5 | 10 | 10 | 4 | 44 |
The record gives a start of Jun 2007, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2010, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetaminophen